Ubs Group Ag Arcutis Biotherapeutics, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 2,920,008 shares of ARQT stock, worth $38.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,920,008

Previous 2,789,530 4.68%

Holding current value

$38.1 Million

Previous $38.9 Million 17.53%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$11.4 - $17.29 $1.49 Million - $2.26 Million	130,478 Added 4.68%	2,920,008 $45.7 Million
Q4 2024 Feb 14, 2025	BUY	$8.31 - $14.99 $21.4 Million - $38.5 Million	2,569,336 Added 1166.85%	2,789,530 $38.9 Million
Q3 2024 Nov 14, 2024	SELL	$8.32 - $11.0 $743,616 - $983,147	-89,377 Reduced 28.87%	220,194 $2.05 Million
Q2 2024 Aug 13, 2024	SELL	$7.24 - $12.53 $1.31 Million - $2.27 Million	-181,106 Reduced 36.91%	309,571 $2.88 Million
Q1 2024 May 13, 2024	BUY	$3.25 - $11.77 $1.59 Million - $5.75 Million	488,577 Added 23265.57%	490,677 $4.86 Million
Q4 2023 Feb 09, 2024	SELL	$1.84 - $4.82 $114,157 - $299,042	-62,042 Reduced 96.73%	2,100 $6,000
Q3 2023 Nov 09, 2023	SELL	$5.31 - $10.98 $401,489 - $830,197	-75,610 Reduced 54.1%	64,142 $340,000
Q2 2023 Aug 11, 2023	BUY	$7.51 - $15.0 $382,807 - $764,595	50,973 Added 57.42%	139,752 $1.33 Million
Q1 2023 May 12, 2023	SELL	$10.23 - $17.14 $1.07 Million - $1.79 Million	-104,532 Reduced 54.07%	88,779 $976,000
Q4 2022 Feb 08, 2023	BUY	$13.96 - $20.4 $2.37 Million - $3.46 Million	169,739 Added 720.09%	193,311 $2.86 Million
Q3 2022 Nov 10, 2022	BUY	$17.85 - $26.95 $122,326 - $184,688	6,853 Added 40.99%	23,572 $450,000
Q2 2022 Aug 10, 2022	SELL	$16.33 - $22.2 $613,730 - $834,342	-37,583 Reduced 69.21%	16,719 $357,000
Q1 2022 May 16, 2022	SELL	$14.38 - $22.79 $5,191 - $8,227	-361 Reduced 0.66%	54,302 $1.05 Million
Q4 2021 Feb 14, 2022	BUY	$14.98 - $25.5 $367,129 - $624,954	24,508 Added 81.27%	54,663 $1.13 Million
Q3 2021 Nov 15, 2021	BUY	$19.28 - $27.1 $363,717 - $511,241	18,865 Added 167.09%	30,155 $720,000
Q2 2021 Aug 13, 2021	SELL	$24.42 - $34.75 $223,589 - $318,171	-9,156 Reduced 44.78%	11,290 $309,000
Q1 2021 May 12, 2021	BUY	$24.47 - $36.98 $500,313 - $756,093	20,446 New	20,446 $591,000
Q4 2020 Feb 11, 2021	SELL	$17.82 - $31.73 $10,923 - $19,450	-613 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$23.44 - $32.28 $58,529 - $80,603	-2,497 Reduced 80.29%	613 $18,000
Q2 2020 Jul 31, 2020	SELL	$24.48 - $36.56 $82,203 - $122,768	-3,358 Reduced 51.92%	3,110 $94,000
Q1 2020 May 01, 2020	BUY	$18.5 - $36.9 $119,658 - $238,669	6,468 New	6,468 $193,000

Others Institutions Holding ARQT

# of Institutions

251

Shares Held

126M

Call Options Held

605K

Put Options Held

170K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $785M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account